ANASTROZOLE REVIEW | BUY ANASTROZOLE 1MG PER ML (30ML)

Disclaimer-lotilabs-banner

ANASTROZOLE REVIEW | BUY ANASTROZOLE 1MG PER ML (30ML)

Anastrozole is a third-generation aromatase inhibitor used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer in postmenopausal animal test subjects. 

It is sold in liquid form in 1mg per ml vials for research and analytical purposes.

WHAT IS ANASTROZOLE?

Anastrozole is an anti-aromatase hormone that works by blocking estrogen synthesis. 

Several adjuvant randomized trials have reported greater efficacy for anastrozole compared to tamoxifen.

According to the data obtained through clinical studies on rats, anastrozole treated breast cancer cells by shrinking them, making it a potential antineoplastic agent. It may also inhibit androstenedione-induced uterine hypertrophy in sexually immature rats.

STRUCTURE OF ANASTROZOLE

Molecular Formula: C17H19N5

Molecular weight: 293.4g/mol

CAS number: 120511-73-1

IUPAC name: 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile

MECHANISM OF ACTION

Anastrozole is a nonsteroidal third-generation aromatase inhibitor. It selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex that interferes with estradiol production in peripheral tissues, including those of the premenopausal ovary, liver, breast, and other fatty tissues.

Because estrogen acts as a growth factor for hormone-dependent breast cancer cells, anastrozole may treat animal test models with breast cancer caused by estrogen. 

Anastrozole has a relatively long duration of action, allowing for once-daily dosing. Its elimination half-life is approximately 50 hours.

ANASTROZOLE EFFECTS

Anastrozole benefits in animal test subjects include:

  • The first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer.
  • Beneficial as an adjunct therapy for hormone receptor-positive early breast cancer in postmenopausal test subjects.
  • Treating peripheral precocious puberty.
  • Balancing testosterone levels in infertile male animals.

ANASTROZOLE SIDE EFFECTS

The side effects of anastrozole seen in animal test subjects include:

  • Hot flashes
  • Asthenia 
  • Joint disorders such as arthritis and arthralgia
  • Osteoporosis
  • Bone pain 
  • Back pain
  • Vaginal dryness
  • Hypertension
  • Hyperlipidemia
  • Hypercholesterolemia
  • Thromboembolic disease, cardiac and cerebrovascular events, insomnia

LOOKING FOR WHERE TO BUY ANASTROZOLE ONLINE

When searching for research liquids online, it is paramount to buy from a trusted laboratory to ensure the integrity of your research. 

Loti Labs offers affordable prices that come with quality control reports. We have in-depth customer support and a generous return policy when you buy anastrozole for sale. 

Visit our website or contact us today to buy anastrozole online.

References:

  1. Giulio Evangelisti, Fabio Barra, Umberto Perrone, Nadine Di Donato, Stefano Bogliolo, Marcello Ceccaroni, Simone Ferrero. (2022) Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids. Expert Opinion on Drug Metabolism & Toxicology 18:7-8, pages 441-457.
  1. Ralf Regenthal, Margarita Voskanian, Frank Baumann, Jens Teichert, Christian Brätter, Achim Aigner, Getu Abraham. (2018) Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Design, Development and Therapy 12, pages 3653-3664.
  1. Yuzhu Zhang, Jingjing Wu, Yue Zhou, Yulian Yin, Hongfeng Chen. (2018) Effects of psoralen on the pharmacokinetics of anastrozole in rats. Pharmaceutical Biology 56:1, pages 433-439.
  1. Maria da Conceição Barros-Oliveira, Danylo Rafhael Costa-Silva, Danielle Benigno de Andrade, Umbelina Soares Borges, Vladimir Costa Silva, Rafael Soares Borges, Pedro Vitor Lopes-Costa, Airlane Pereira Alencar, Benedito Borges da Silva. (2017) Ki-67 antigen expression in the mammary epithelium of female rats in persistent estrus treated with anastrozole. Gynecological Endocrinology 33:5, pages 359-362.

Share this post